Back

Discussant review: Does intensive treat-to-target LDL-C lowering therapy using statin in patients of diabetic retinopathy reduce cardiovascular events?: the EMPATHY study

29 August 2017 (09:01 - 09:06)
Organised by:
Congress Presentation Part of: Hot Line: Late-Breaking Clinical Trials 4 Diabetes, dysglycaemia and metabolic syndrome ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Eva Prescott

Bispebjerg University Hospital, Copenhagen (Denmark)

12 More presentations in this session

Presentation thumbnail
Clinical effects of anacetrapib in people with established vascular disease: Results of the Randomized EValuation of the Effects of Anacetrapib through Lipid-modification (HPS3/TIMI55-REVEAL) trial
Professor M. Landray (Oxford, GB)
Slides Video
Presentation thumbnail
Discussant review: Clinical effects of anacetrapib in people with established vascular disease: Results of the Randomized EValuation of the Effects of Anacetrapib through Lipid-modification (HPS3/TIMI55-REVEAL) trial
Professor J. Chapman (Paris, FR)
Slides Video
Presentation thumbnail
Panel discussion.
Video
Presentation thumbnail
Does intensive treat-to-target LDL-C lowering therapy using statin in patients of diabetic retinopathy reduce cardiovascular events?: the EMPATHY study
Professor H. Itoh (Tokyo, JP)
Slides Video
Presentation thumbnail
Panel discussion.
Video

Access the full session

Session thumbnail
Hot Line: Late-Breaking Clinical Trials 4

The Event

Event poster

ESC Congress 2017

29 August 2017 09:01 CET
You may be interested in
thumbnail
Congress Session
Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes
27 August 2023
thumbnail
Congress Presentation
LDL treatment-years: a new paradigm for cardiovascular risk reduction
1 September 2025
thumbnail
Congress Presentation
Triglyceride lowering after MI
1 September 2025
thumbnail
Congress Presentation
Carotid plaques stabilization and regression with evolocumab
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources